Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2130

Sort by

Sort Order Select

Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4374.

https://doi.org/10.1182/blood-2019-128041

Published: 2019

Journal Articles

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

Loula Papageorgiou, Patrick Van Dreden, PhD, Meletios A. Dimopoulos, MD, Annette Larsen, Mohamad Mohty, MD PhD, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas

Blood (2019) 134 (Supplement_1): 2425.

https://doi.org/10.1182/blood-2019-124650

Published: 2019

Journal Articles

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

Natthakan Thongon, PhD, Christopher Jackson, BS, Pamela Lockyer, MS, Jintan Liu, Andrea Santoni, PhD, Ashley Rose, BS, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2019) 134 (Supplement_1): 685.

https://doi.org/10.1182/blood-2019-129286

Published: 2019

Journal Articles

Targeting Bcl-2 Proteins in Myeloma

Martine Amiot, PhD

Blood (2019) 134 (Supplement_1): SCI-11.

https://doi.org/10.1182/blood-2019-121103

Published: 2019

Journal Articles

Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology

Alexia Katsarou, Nikolaos Trasanidis, Jaime Alvarez-Benayas, Foteini Papaleonidopoulou, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Xiaolin Xiao, Niklas Feldhahn, Irene Roberts, Evdoxia Hatjiharissi, Maria Papaioannou, Ian Sudbery, Aristeidis Chaidos, Valentina S Caputo, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 3783.

https://doi.org/10.1182/blood-2019-122371

Published: 2019

Journal Articles

PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup

Nikolaos Trasanidis, Alexia Katsarou, Bien Bergonia, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Reema Paudel, Xiaolin Xiao, Holger W Auner, MD PhD, Irene Roberts, Kikkeri Naresh, MD, Aristeidis Chaidos, Luca Magnani, Valentina S Caputo, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 3760.

https://doi.org/10.1182/blood-2019-124109

Published: 2019

Journal Articles

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

Kim De Veirman, Siyang Yan, Ken Maes, Nathan De Beule, MD, Sylvia Faict, MSc, Elke De Bruyne, PhD, Eline Menu, PhD, Karin Vanderkerken, PhD

Blood (2019) 134 (Supplement_1): 4335.

https://doi.org/10.1182/blood-2019-126834

Published: 2019

Journal Articles

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Chang-Xin Shi, PhD, Yuan Xiao Zhu, PhD, Laura Ann Bruins, BS, Cecilia Bonolo De Campos, PhD, William Stewart, Esteban Braggio, PhD, A Keith Stewart, M.B. Ch.B.

Blood (2019) 134 (Supplement_1): 4337.

https://doi.org/10.1182/blood-2019-127149

Published: 2019

Journal Articles

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

Evangelos Terpos, MD PhD, Ioannis V. Kostopoulos, Aristea-Maria Papanota, MD, Konstantinos Papadimitriou, BSc, Panagiotis Malandrakis, MD, Paraskevi Micheli, BSc, Ioannis Ntanasis-Stathopoulos, MD, Despina Fotiou, MD, Andreas Metousis, BSc, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Eftathios Kastritis, Ourania E. Tsitsilonis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4338.

https://doi.org/10.1182/blood-2019-127989

Published: 2019

Journal Articles

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Martina Chiu, PhD, Denise Toscani, PhD, Emanuela Vicario, PhD, Roberta Andreoli, PhD, Giuseppe Taurino, MS, Valentina Marchica, MS, Paola Storti, PhD, Massimiliano Bianchi, PhD, Ovidio Bussolati, MD PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 4339.

https://doi.org/10.1182/blood-2019-128034

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

Mohamed Rizk, BSc, MSc, Ola Rizq, MD PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Shuhei Koide, PhD, Atsunori Saraya, Yusuke Isshiki, MD PhD, Tetsuhiro Chiba, MD PhD, Satoshi Yamazaki, PhD, Anqi Ma, PhD, Jian Jin, PhD, Atsushi Iwama, MD PhD, Naoya Mimura, MD PhD

Blood (2019) 134 (Supplement_1): 4400.

https://doi.org/10.1182/blood-2019-122157

Published: 2019

Journal Articles

Targeting Glycolysis in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant in Hypoxic Conditions

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD

Blood (2019) 134 (Supplement_1): 4344.

https://doi.org/10.1182/blood-2019-129818

Published: 2019

Journal Articles

Risk Factors and Characteristics of CRS in CAR-T Treatment

Yan Zhiling, MD, Zhang Huanxin, MD, Ying Wang, Jiang Cao, MD, Jianlin Qiao, PhD, Deipeng Li, MD, Bin Pan, MD, Qingyun Wu, PhD, Zhenyu Li, MD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 4462.

https://doi.org/10.1182/blood-2019-129777

Published: 2019

Journal Articles

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Rafael Alonso Fernández, MD, Laetitia Pierre-Louis, Rao Prabhala, Yan Xu, MD, Joaquin Martinez-Lopez, MD PhD, Takahiro Miyazaki, Mehmet Kemal Samur, PhD, Loui Madakamutil, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4398.

https://doi.org/10.1182/blood-2019-128767

Published: 2019

Journal Articles

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Nina D. Shah, MD, Cameron J. Turtle, MBBS, PhD, Andrew J. Cowan, MD, Julio C. Chavez, MD, Lihua E Budde, MD PhD, Mario Q. Marcondes, MD PhD, Zachary Lee, PharmD, Wei Lin, MD, Jonathan Zalevsky, Mary Tagliaferri, MD, Krina K. Patel, MDMSc

Blood (2019) 134 (Supplement_1): 4459.

https://doi.org/10.1182/blood-2019-122494

Published: 2019

Journal Articles

Novel ZBP1-IRF3 Dependency in Multiple Myeloma Mediated By IRF3-Driven Regulation of Cell Cycle Genes

Kanagaraju Ponnusamy, Maria-Myrsini Tzioni, MS, Murshida Begum, MS, Mark E Robinson, Valentina S Caputo, Alexia Katsarou, Nikolaos Trasanidis, Xiaolin Xiao, Ioannis V. Kostopoulos, Deena Iskander, MD, Irene Roberts, Pritesh Trivedi, MSc, Holger W Auner, MD PhD, Kikkeri Naresh, MD, Aristeidis Chaidos, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 2521.

https://doi.org/10.1182/blood-2019-125768

Published: 2019

Journal Articles

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Vassilis L. Souliotis, PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 2528.

https://doi.org/10.1182/blood-2019-123338

Published: 2019

Journal Articles

Quantitative Proteomic Analysis of Relapsed Multiple Myeloma Identifies CDK6 Upregulation As a Potential Targetable Resistance Mechanism for Lenalidomide

Yuen Lam Dora Ng, Stephan Bohl, Evelyn Ramberger, Oliver Popp, Imke Bauhuf, Anna Dolnik, Christian Steinebach, Michael Gütschow, Lars Bullinger, Philipp Mertins, Jan Kroenke

Blood (2019) 134 (Supplement_1): 2567.

https://doi.org/10.1182/blood-2019-130682

Published: 2019

Journal Articles

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS

Ruth Wester, M Duin, King Hong Lam, MD PhD, Suzana Couto, Yan Ren, Maria Wang, Bronno Van Der Holt, PhD, Berna Berna Beverloo, PhD, Heleen Visser-Wisselaar, Alex Nigg, Anjan Thakurta, Sonja Zweegman, Annemiek Broyl, MD PhD, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 3071.

https://doi.org/10.1182/blood-2019-128584

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

Targeting Bcl-2 Proteins in Myeloma

Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology

PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

Targeting Glycolysis in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant in Hypoxic Conditions

Risk Factors and Characteristics of CRS in CAR-T Treatment

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Novel ZBP1-IRF3 Dependency in Multiple Myeloma Mediated By IRF3-Driven Regulation of Cell Cycle Genes

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Quantitative Proteomic Analysis of Relapsed Multiple Myeloma Identifies CDK6 Upregulation As a Potential Targetable Resistance Mechanism for Lenalidomide

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only